| [1] |
Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized Intergroup study 0099[J]. J Clin Oncol, 1998, 16 (4):1310-1317. DOI:10.1200/JCO.1998.16.4.1310.
|
| [2] |
Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2005, 97 (7):536-539. DOI:10.1093/jnci/dji084.
|
| [3] |
Shah BA, Qureshi MM, Jalisi S, et al. Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines[J]. Pract Radiat Oncol, 2016, 6 (4):248-254. DOI:10.1016/j.prro.2015.11.006.
|
| [4] |
Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC):an update on 93 randomised trials and 17, 346 patients[J]. Radiother Oncol, 2009, 92 (1):4-14. DOI:10.1016/j.radonc.2009.04.014.
|
| [5] |
Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers:an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group[J]. J Clin Oncol, 2013, 31 (23):2854-2860. DOI:10.1200/JCO.2012. 47.7802.
|
| [6] |
Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J]. J Clin Oncol, 2009, 27 (2):242-249. DOI:10.1200/JCO.2008. 18. 1545.
|
| [7] |
Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trial 0225[J]. J Clin Oncol, 2009, 27 (22):3684-3690. DOI:10.1200/JCO.2008.19.9109.
|
| [8] |
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47 (1):207-214. doi: 10.1002/(ISSN)1097-0142
|
| [9] |
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncolog y Group (RTOG) and the European organization for research and treatment of cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31 (5):1341-1346. doi: 10.1016/0360-3016(95)00060-C
|
| [10] |
Lin JC, Jan JS, Hsu CY, et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival[J]. J Clin Oncol, 2003, 21 (4):631-637. DOI:10.1200/JCO.2003.06.158.
|
| [11] |
Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:progression-free survival analysis of a phase Ⅲ randomized trial[J]. J Clin Oncol, 2002, 20 (8):2038-2044. DOI:10.1200/JCO.2002.08.149.
|
| [12] |
Jagdis A, Laskin J, Hao D, et al. Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC)[J]. Am J Clin Oncol, 2014, 37 (1):63-69. DOI:10.1097/COC.0b013e31826b9b1a.
|
| [13] |
Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer:a retrospective comparison from New Cross Hospital, Wolverhampton, UK[J]. Acta Oncol, 2008, 47 (8):1513-1518. DOI:10.1080/02841860701846160.
|
| [14] |
Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma:combined analyses of NPC-9901 and NPC-9902 Trials[J]. Eur J Cancer, 2011, 47 (5):656-666. DOI:10.1016/j.ejca.2010.10.026.
|
| [15] |
Loong HH, Ma BB, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104 (3):300-304. DOI:10.1016/j.radonc.2011.12.022.
|
| [16] |
Meng DF, Sun R, Peng LX, et al. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy:a matched study[J]. J Cancer, 2018, 9 (1):92-99. DOI:10.7150/jca.21357.
|
| [17] |
Kong L, Hu C, Niu X, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma:interim results from 2 prospective phase 2 clinical trials[J]. Cancer, 2013, 119 (23):4111-4118. DOI:10.1002/cncr.28324.
|
| [18] |
Zhong YH, Dai J, Wang XY, et al. Phase Ⅱ trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 2013, 71 (6):1577-1583. DOI:10.1007/s00280-013-2157-2.
|
| [19] |
Ou X, Zhou X, Shi Q, et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy:new insight into the value of total dose of cisplatin and radiation boost[J]. Oncotarget, 2015, 6 (35):38381-38397. DOI:10.18632/oncotarget.5420.
|
| [20] |
Sun X, Su S, Chen C, et al. Long-term outcomes of intensitymodulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110 (3):398-403. DOI:10.1016/j.radonc.2013.10.020.
|